EP1853264A1 - Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes - Google Patents
Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetesInfo
- Publication number
- EP1853264A1 EP1853264A1 EP06709344A EP06709344A EP1853264A1 EP 1853264 A1 EP1853264 A1 EP 1853264A1 EP 06709344 A EP06709344 A EP 06709344A EP 06709344 A EP06709344 A EP 06709344A EP 1853264 A1 EP1853264 A1 EP 1853264A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- rimonabant
- treatment
- diabetes
- prevention
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Definitions
- the present invention relates to the use of rimonabant, for the preparation of drugs useful in the prevention and treatment of type 2 diabetes or non-insulin-dependent diabetes and / or its complications.
- Type 2 diabetes is characterized by insulin secretion disorders associated with insulin sensitivity or insulin resistance disorders. Insulin resistance is aggravated by hyperglycemia and high levels of circulating free fatty acids and stored triglycerides.
- Rimonabant is the international nonproprietary name of N-piperidino-5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide described in European Patent 656354. Clinical studies conducted with rimonabant have shown that it acts on quantitative and qualitative food intake and reduces the body weight of obese patients (Le Fur, 2003, 35, First European Workshop on Cannabinoid Research,
- rimonabant can be used for the preparation of medicaments useful for preventing and treating type 2 diabetes and its complications.
- Diabetes-related complications include:
- neurological diseases such as diabetic neuropathies, peripheral neuropathies, autonomic cardiac neuropathies;
- kidney diseases such as diabetic nephropathies, diabetic glomerulopathies
- ocular diseases such as diabetic retinopathies, macular edema, glaucoma;
- the subject of the present invention is the use of rimonabant for the prevention and treatment of complications related to diabetes, while particularly, peripheral neuropathies, diabetic neuropathies, diabetic nephropathies, diabetic retinopathies, angiopathies.
- compositions according to the present invention contain an effective dose of rimonabant as well as at least one pharmaceutically acceptable excipient.
- Said excipients are chosen according to the pharmaceutical form and the desired mode of administration, from the usual excipients which are known to those skilled in the art.
- the active ingredient may be administered in unit dosage form. in combination with conventional pharmaceutical excipients, animals and humans for the prevention or treatment of type 2 diabetes.
- Suitable dosage unit forms include oral forms such as tablets, soft or hard capsules , powders, granules and oral solutions or suspensions, sublingual, oral, intratracheal, intraocular, intranasal, inhalation, forms of topical, transdermal, subcutaneous, intramuscular or intravenous administration, rectal administration and implants.
- the compounds according to the invention can be used in creams, gels, ointments or lotions.
- capsules or tablets are preferred. More particularly, capsules or tablets containing rimonabant are preferred at a dose of between 5 and 50 mg, more particularly at doses of 10 to 30 mg, especially the dose of 20 mg.
- the rimonabant can be associated with another active principle chosen from one of the following therapeutic classes: a lipid-lowering agent or a cholesterol-lowering agent;
- compositions containing, in combination, a cannabinoid CB 1 receptor antagonist, derived from pyrazole, chosen from rimonabant and N-piperidino-5- (4- bromophenyl) -1- (2,4-dichlorophenyl) -4-ethylpyrazole-3-carboxanide, and another active ingredient selected from one of the following therapeutic classes:
- lipid-lowering agent or a cholesterol-lowering agent
- lipid-lowering or cholesterol-lowering agent a compound chosen from fibrates such as alufibrate, beclobrate, bezafibrate, ciprofibrate, clinofibrate, clofibrate, etofibrate, fenofibrate; statins (HMG-CoA reductase inhibitors), such as atorvastatin, fluvastatin sodium, lovastatin, pravastatin, rosuvastatin, simvastatin, or a compound such as acipimox, aluminum nicotinate, azacosterol, cholestyramine, dextrothyroxine, meglutol, niceritrol, nicoclonate, nicotinic acid , beta-sitosterin, tiadenol.
- statins HMG-CoA reductase inhibitors
- statins HMG-CoA reductase inhibitors
- antidiabetic means a compound belonging to one of the following classes: sulfonylureas, biguanidines, alpha glucosidase inhibitors, thiazolidinedione, methaglinides, such as acarbose, acetohexamide, carbutamide, chlorpropamide, glibenclamide, glibornuride, gliclazide, glimepiride, glipizide, gliquidone, glisoxepide, glybuzole, glymidine, metahexamide, metformin, miglitol, nateglinide, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide, voglibose.
- methaglinides such as acarbose, acetohexamide, carbutamide, chlorpropamide, glibenclamide, glibornuride, glicla
- the subject of the present invention is a pharmaceutical composition containing, in combination, rimonabant and metformin, or rimonabant and a sulphonylurea such as acetohexamide, carbutamide, chlorpropamide, glibenclamide, glibornuride, gliclazide, glimepiride, glipizide, tolazamide, tolbutamide, for the treatment of type 2 diabetes.
- a sulphonylurea such as acetohexamide, carbutamide, chlorpropamide, glibenclamide, glibornuride, gliclazide, glimepiride, glipizide, tolazamide, tolbutamide
- the rimonabant and the other associated active ingredient can be administered simultaneously, separately or spread over time.
- Extended use over time is understood to mean the sequential administration of the first compound of the composition according to the invention, included in a pharmaceutical form, then, of the second compound of the composition according to the invention, included in a form pharmaceutical industry.
- the lapse of time elapsed between the administration of the first compound of the composition according to the invention and the administration of the second compound of the same composition according to the invention does not exceed usually not 24 hours, it can be higher if one or the other
- the compounds are presented in a pharmaceutical formulation allowing, for example, a weekly administration.
- compositions according to the invention comprising either one of the constituent compounds of the composition according to the invention or the combination of the two compounds, which can be used in the various types of use described above, may for example be appropriate for oral, nasal, parenteral or transdermal administration.
- two different dosage forms may be for the same route of administration or a different route of administration (oral and transdermal). or oral and nasal or parenteral and transdermal etc).
- the invention therefore also relates to a kit containing the rimonabant and another active ingredient or, where appropriate, two associated active principles in which the rimonabant and said active ingredient or, where appropriate, two associated active ingredients are in separate compartments and in similar or different packages, and are intended to be administered simultaneously, separately or spread over time.
- EXAMPLE 1 Action of rimonabant on overweight or obese type diabetic patients.
- the Rio-Diabete clinical trial conducted for 12 months in 1045 obese subjects with type 2 diabetes treated with monotherapy (metformin or sulfonylureas) compares the effect of rimonabant to the 20 mg dose versus a placebo product in the reduction of weight; improvement in glycosylated hemoglobin (HbAIc), blood glucose, insulinemia and lipid parameters.
- a low-calorie diet (deficit of 600 Kcal / day) is prescribed for all patients and is initiated 4 weeks before the start of the treatment period.
- a decrease in fasting blood glucose of 0.64 ⁇ 1.96 mmol / L was observed in the rimonabant 20 mg group, compared to an increase of 0.33 ⁇ 2.32 mmol / L in the placebo group (p ⁇ 0.001 ).
- Insulin resistance is evaluated by the Homeostasis Model Assessment (HOMA) test described by Matthew D.R. et al. in Diabetologica, 1985, 28, 412-
- HOMA Homeostasis Model Assessment
- Triglycerides were decreased by more than 16.4 ⁇ 3.3% in the treated group compared with the placebo group (p ⁇ 0.001). Following a logistic regression analysis in which weight is introduced as a variable cost, an effect independent of weight loss of approximately 55% for the improvement of PHbAIc and HDL-c and approximately 35%. % for triglycerides is observed in this study.
- rimonabant induces a significant weight loss: the difference in weight loss compared to the placebo group is 4.3 ⁇ 0.4 kg (p ⁇ 0.001) when rimonabant-metformin combination; it is 3.1 ⁇ 0.5 kg (p ⁇ 0.001) during rimonabant-sulfonylurea combination.
- the effect of long-term (12 months) treatment with rimonabant was studied in Zucker rats with established obesity.
- the fa / fa strain of Zucker obese rats is characterized by hyperphagia, obesity, dyslipidemia and type 2 diabetes.
- the experiment is carried out with the rimonabant administered orally with 3 yes 0 mg / kg.
- the animals were treated daily from the 7 th day after injection of streptozotocin, for a period of 7 weeks. Sensitivity to a mechanical stimulus is determined by the Von Frey filament
- anesthesiometer by measuring the threshold of withdrawal of the paw in response to mechanical nociceptive stimulation.
- a rigid polypropylene tip is used to apply a force to the plantar surface of the paw.
- the force inducing a withdrawal response is recorded.
- the test is repeated 3 times at approximately 5 min intervals for each animal and the average value is calculated.
- VCNS is measured according to the method described by P. De Koning et al. in Peptides: 1987; 8 (3): 415-22.
- the rats are anesthetized by an injection of 30 mg / kg of pentobarbital, the sciatic and fibular nerves are stimulated successively with the aid of monopolar electrodes, respectively at the notch of the sciatic nerve and the fibular nerve (at the level of ankle). Responses are recorded at the arch by surface electrodes.
- the VCNS is calculated from the latencies of these responses by subtracting the distal latency from the proximal and the result divided by the distance between the stimulating and receiving electrodes.
- Diabetic rats develop mechanical hyperalgesia, which is manifest as an approximate 40% reduction in the paw withdrawal threshold in response to mechanical nociceptive stimulation. This deficit is completely repaid (100%) by the treatment with rimonabant at doses of 3 or 10 mg / kg po after 7 weeks of treatment.
- VCNS was reduced by 22% in diabetic rats compared to control rats; and treatment with rimonabant at 10 mg / kg partially reduced (-12%) the deficits of the VCNS, which correspond to 54.5% of deficit reversion.
- rimonabant shows efficacy in this model of treatment of diabetic neuropathy.
- rimonabant is formulated into pharmaceutical compositions which are prepared by wet granulation.
- Povidone is defined in the European Pharmacopoeia as follows: poly (1- (2-oxo-1-pyrrolidinyl) ethylene) and consists of linear polymers of 1-vinylpyrrolidin-2-one.
- the tablets are preferably coated using a suitable excipient.
Abstract
Description
Claims
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0501861A FR2882261B1 (en) | 2005-02-21 | 2005-02-21 | USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES |
FR0504942A FR2882264A1 (en) | 2005-02-21 | 2005-05-12 | Use of rimonabant and N-peperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide, having cannabinoids receptor antagonistic activity, to treat and prevent type-II diabetes |
FR0505228A FR2882265B1 (en) | 2005-02-21 | 2005-05-23 | USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES. |
PCT/FR2006/000376 WO2006087481A1 (en) | 2005-02-21 | 2006-02-20 | Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1853264A1 true EP1853264A1 (en) | 2007-11-14 |
Family
ID=36218441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06709344A Withdrawn EP1853264A1 (en) | 2005-02-21 | 2006-02-20 | Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes |
Country Status (9)
Country | Link |
---|---|
US (2) | US20080015229A1 (en) |
EP (1) | EP1853264A1 (en) |
KR (1) | KR20070104913A (en) |
AR (1) | AR053812A1 (en) |
AU (1) | AU2006215444A1 (en) |
CA (1) | CA2597245A1 (en) |
NO (1) | NO20074767L (en) |
UY (1) | UY29386A1 (en) |
WO (1) | WO2006087481A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010502670A (en) * | 2006-09-07 | 2010-01-28 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination therapy for diabetes mellitus |
WO2010079241A1 (en) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Use of antagonists and/or inverse agonists of cb1 receptors for the preparation of drugs that increase motor neuron excitability |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
FR2758723B1 (en) * | 1997-01-28 | 1999-04-23 | Sanofi Sa | USE OF CENTRAL CANNABINOID RECEPTOR ANTAGONISTS FOR THE PREPARATION OF DRUGS |
FR2789079B3 (en) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | PYRAZOLECARBOXYLIC ACID DERIVATIVE, ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
US20040122033A1 (en) * | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
-
2006
- 2006-02-20 WO PCT/FR2006/000376 patent/WO2006087481A1/en active Application Filing
- 2006-02-20 AU AU2006215444A patent/AU2006215444A1/en not_active Abandoned
- 2006-02-20 CA CA002597245A patent/CA2597245A1/en not_active Abandoned
- 2006-02-20 KR KR1020077018993A patent/KR20070104913A/en not_active Application Discontinuation
- 2006-02-20 EP EP06709344A patent/EP1853264A1/en not_active Withdrawn
- 2006-02-20 UY UY29386A patent/UY29386A1/en not_active Application Discontinuation
- 2006-02-21 AR ARP060100611A patent/AR053812A1/en unknown
-
2007
- 2007-08-02 US US11/832,865 patent/US20080015229A1/en not_active Abandoned
- 2007-09-18 NO NO20074767A patent/NO20074767L/en not_active Application Discontinuation
-
2009
- 2009-03-12 US US12/402,988 patent/US20090197917A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2006087481A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2597245A1 (en) | 2006-08-24 |
WO2006087481A1 (en) | 2006-08-24 |
US20090197917A1 (en) | 2009-08-06 |
AU2006215444A1 (en) | 2006-08-24 |
KR20070104913A (en) | 2007-10-29 |
NO20074767L (en) | 2007-11-20 |
US20080015229A1 (en) | 2008-01-17 |
UY29386A1 (en) | 2006-10-02 |
AR053812A1 (en) | 2007-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1377278B1 (en) | Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv | |
EP1283708B1 (en) | Use of biguanide derivatives for making a medicine having a wound healing effect | |
US20040068005A1 (en) | Pharmaceutical combinations | |
EA015382B1 (en) | Use of roflumilast for the treatment of diabetes mellitus type 2 | |
JP2001509173A (en) | Use of gastrointestinal lipase inhibitors | |
CA2543582A1 (en) | Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity | |
DE602004012763T2 (en) | PHARMACEUTICAL COMPOSITION COMPRISING A SELECTIVE I1 IMIDAZOLINE RECEPTOR AGONIST AND AN ANGIOTENSIN II RECEPTOR BLOCKER | |
EP1853264A1 (en) | Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes | |
CN113613653A (en) | Method of treating borderline personality disorder | |
FR2882261A1 (en) | Use of cannabinoid receptor antagonists, preferably rimonabant or N-piperidino-5-(4-bromophenyl)-1- (2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide, for the preparation of drugs in the treatment and prevention of type-2 diabetes | |
US20080255238A1 (en) | Composition containing a thiourea derivative for preventing or treating pruritic or irritant skin diseases | |
CA2597802A1 (en) | Use of a pyrazole derivative for preparing medicines useful for preventing or treating renal diseases | |
FR2758460A1 (en) | USE OF ADRENERGIC BETA-3 RECEPTOR AGONISTS FOR THE PREPARATION OF HEALING MEDICINAL PRODUCTS | |
JP7257091B2 (en) | Dementia treatment and preventive drug | |
EP3967308A1 (en) | Mepyramine for use in the topical treatment of neuropathic pain | |
FR2861301A1 (en) | Use of pyrazole derivative as cannabinoid CB1 receptor antagonist, for treatment and prevention of metabolic syndrome, particularly cardiovascular risks and dyslipidemia associated with obesity | |
FR2882264A1 (en) | Use of rimonabant and N-peperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide, having cannabinoids receptor antagonistic activity, to treat and prevent type-II diabetes | |
WO1996028161A1 (en) | Use of a 2-(4-(azolylbutyl)-piperazinyl-methyl)-benzimidazole derivative for treating allergic conjunctivitis | |
WO2008110697A2 (en) | Use of a compound antagonist to the nk2 receptors of a neurokinine for the preparation of drugs useful for preventing and treating sexual dysfunction | |
FR2576788A1 (en) | PHARMACEUTICAL COMPOSITIONS BASED ON 3-AMINOPROPOXYINDOLES | |
FR2861302A1 (en) | Use of pyrazole derivative as cannabinoid CB1 receptor antagonist, for treatment and prevention of metabolic syndrome, particularly cardiovascular risks and dyslipidemia associated with obesity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070921 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SANOFI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SANOFI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SANOFI |
|
17Q | First examination report despatched |
Effective date: 20130215 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20160901 |